The Drug That Works Best on Paper Also Comes With Four Years of Watching
Aggressive early MS, one failed first-line drug, and the strongest agent on the shelf — which the label says to hold back until two drugs have failed. Severity argues for reaching now; the label argues for one more trial first. Only her next scan can tell the group which read was right, and only after it commits.
Three relapses in fourteen months is the number that has brought P.J., who is 24, back to clinic ahead of schedule. She is a graduate student in structural biology, and the dissertation defense her funding renewal is tied to now sits behind a more immediate problem: the most recent attack cost her a week of bench work she cannot easily rebuild, and her MRI has picked up new cervical cord and brainstem lesions, two of them enhancing. Her EDSS was 1.5 at diagnosis. It is 3.5 today. Interferon beta-1a has not held her.
Alemtuzumab is on the table because CARE-MS II tested exactly her situation — patients relapsing through a first-line drug — and reported both a halved relapse rate and a real reduction in confirmed disability progression against interferon. Two points complicate reaching for it. The first is what follows the two short annual courses: autoimmune thyroid disease in roughly a third of treated patients, ITP in about two percent, a rare glomerular nephropathy, and four years of monthly bloods and urinalysis after her last infusion. The second is easier to miss and harder to argue with once seen. The US label says alemtuzumab should generally be reserved for patients who have had an inadequate response to two or more MS drugs, and P.J. has failed exactly one. Nothing about that sentence describes her biology. It describes a sequence — and the question the group actually has to answer is whether a disease moving this fast earns the right to skip a step, or whether skipping it is how you end up unable to say afterward what the step would have shown.
After the third breakthrough relapse in a year
I'd start alemtuzumab. CARE-MS II (Coles et al., 2012) is the trial that actually matches her situation — it enrolled patients who had already broken through a first-line drug, and alemtuzumab cut the annualized relapse rate roughly in half against interferon beta-1a, 0.26 versus 0.52, and dropped six-month confirmed disability progression from 21 percent to 13 percent. I want to be precise that CARE-MS I, the treatment-naive trial, showed the relapse benefit but missed significance on disability, 8 versus 11 percent. So the disability claim rests on CARE-MS II specifically, which is the population she's in.
If she'd had one relapse in a year with a stable EDSS, I wouldn't be reaching for this drug first — it's specifically how fast her disease is moving that makes the efficacy argument outweigh the monitoring burden for me here.
I'd start ocrelizumab or natalizumab instead. Autoimmune thyroid disorders occurred in about 34 percent of alemtuzumab-treated patients in the clinical studies, with roughly 2 percent developing ITP and about 0.3 percent a glomerular nephropathy — and the monitoring that goes with it is monthly CBC, serum creatinine and urinalysis until 48 months after her last infusion, thyroid function every three months, plus annual skin exams for melanoma. That efficacy edge was strongest when this was the only high-efficacy option. It isn't anymore.
You're right that CARE-MS II is the trial that matches her, and I'm not disputing its result — but that's the trial, not the label. The US prescribing information says alemtuzumab should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for MS. She has failed one. I'm not saying that's an absolute bar, and I'm not saying her severity doesn't matter. I'm saying that if this group starts her on alemtuzumab today, it is deciding to go outside the label's own stated sequencing on the strength of a severity judgment, and that should be said out loud and written in the chart rather than arrived at by accident.
I don't think either of you is wrong about your own evidence, and I don't think this resolves as a general efficacy-versus-safety question. Her disease severity may genuinely exceed what the newer agents' own pivotal trials represent — which means the efficacy comparison between them isn't settled, it's actually unknown for a patient like her.
That cuts both ways, and I want to be honest about that rather than resolve it cleanly toward alemtuzumab. It's just as possible ocrelizumab or natalizumab would control her disease adequately as it is that they'd fall short. And the sequencing point you just made is what tips me, not because a label sentence settles a clinical question, but because it happens to point the same direction the uncertainty does: if we genuinely don't know whether an anti-CD20 agent would hold her, the way to find out costs her one drug trial with close monitoring — and if it doesn't hold her, she then meets the reservation criterion for alemtuzumab on her own history rather than on our argument about it.
Agreed: switch to ocrelizumab now, with MRI at three and six months rather than at a year, and written criteria — any relapse, any new or enhancing lesion — that would move her to alemtuzumab without a fresh round of debate. Varicella serology and pre-treatment vaccination were completed this visit so that an escalation later isn't held up by screening. The MS Neurologist's reading of CARE-MS II was not overruled; what changed the plan was that going to alemtuzumab first would mean stepping outside the label's own reservation on the strength of a severity judgment the group could not actually verify in advance, when one closely watched drug trial can verify it.
Not agreed: whether that reservation should carry this much weight in a patient moving this fast. The MS Neurologist's position was that three relapses in fourteen months is exactly the situation where sequencing rules cost a patient irreversible disability, and he asked that his disagreement be recorded rather than smoothed over. The group did not resolve it — it deferred it to her next scan, which is the one thing that will actually settle whether he was right.